Novomer Completes World’s First Large-Scale PPC Polyol Manufacturing Run

Novomer Completes World’s First Large-Scale PPC Polyol Manufacturing Run

February 20, 2013

WALTHAM, MA – February 20, 2013 – Novomer, Inc., a sustainable materials company pioneering a family of high-performance polymers and other chemicals from renewable feedstocks such as carbon dioxide (CO2), has announced the world's first large-scale manufacturing run of polypropylene carbonate (PPC) polyol, producing over seven tons of finished product. The PPC polyol was scaled up and produced with Albemarle at their Orangeburg, South Carolina manufacturing facility using existing Albemarle equipment, which was modified for PPC polyol production.

Eleven Biotherapeutics Publishes Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease

Eleven Biotherapeutics Publishes Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease

February 19, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Concert Pharmaceuticals Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial for the Treatment of Diabetic Kidney Disease

Concert Pharmaceuticals Announces Completion of Enrollment in Phase 2 CTP-499 Clinical Trial for the Treatment of Diabetic Kidney Disease

February 19, 2013

Ensemble Therapeutics Presents Data Demonstrating Unique Properties of Synthetic Macrocycles for Pursuing Challenging Targets

Ensemble Therapeutics Presents Data Demonstrating Unique Properties of Synthetic Macrocycles for Pursuing Challenging Targets

February 13, 2013

Preclinical Data Showing Benefits of Macrocycle Discovery Platform in Identifying First-in-Class Oral IL-17 Antagonists Presented At Molecular Med Tri Con 2013 Conference

Graham Cooper Appointed Chief Financial Officer of Receptos

Graham Cooper Appointed Chief Financial Officer of Receptos

February 14, 2013

SAN DIEGO, Feb. 14, 2013 /PRNewswire/ -- Receptos, Inc. announced today that Graham Cooper has been appointed Chief Financial Officer. Mr.

Tetraphase Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering

Tetraphase Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering

February 12, 2013

Watertown, MA – February 12, 2013 – Tetraphase Pharmaceuticals, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering.

Concert Pharmaceuticals Announces Milestone Achievement in Avanir Pharmaceuticals Collaboration

Concert Pharmaceuticals Announces Milestone Achievement in Avanir Pharmaceuticals Collaboration

February 7, 2013

LEXINGTON, Mass.--()--Concert Pharmaceuticals, Inc. today announced that it has achieved a milestone under its licensing agreement with Avanir Pharmaceuticals, Inc. for the development of AVP-786 (also known as CTP-786 or deuterated dextromethorphan).

T2 Biosystems Announces Patent Covering T2Hemostasis

T2 Biosystems Announces Patent Covering T2Hemostasis

February 5, 2013

LEXINGTON, Mass.--(BUSINESS WIRE)--

Acceleron Initiates Phase 2 Study of Dalantercept (ACE-041) to Treat Patients with Metastatic Renal Cell Carcinoma

Acceleron Initiates Phase 2 Study of Dalantercept (ACE-041) to Treat Patients with Metastatic Renal Cell Carcinoma

February 5, 2013

One of Seven Phase 2 Studies Across Three Different Acceleron Programs
Initiated in the Last Three Months

Acceleron Announces the Initiation of Phase 2 Clinical Trial of Dalantercept (ACE-041) in Patients with Ovarian Cancer

Acceleron Announces the Initiation of Phase 2 Clinical Trial of Dalantercept (ACE-041) in Patients with Ovarian Cancer

February 5, 2013

Dalantercept Now in Four Phase 2 Studies to Treat Aggressive Cancers with Limited Treatment Options